Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720936 | 0.96 | LMNA (1.00) | LMNATHRB | |
| SCHEMBL7055048 | 0.96 | LMNA (1.00) | LMNATHRB | |
| Perflubrodec SCHEMBL364093 | 0.96 | LMNA (1.00) | LMNATHRB | |
| Perflubron SCHEMBL33826 | 0.96 | LMNA (1.00) | LMNATHRB | |
| SCHEMBL7029311 | 0.96 | LMNA (1.00) | LMNATHRB | |
| Perflubron SCHEMBL8040555 | 0.96 | LMNA (1.00) | LMNATHRB | |
| Perflubron SCHEMBL13724347 | 0.96 | LMNA (1.00) | LMNATHRB | |
| SCHEMBL4511229 | 0.96 | LMNA (1.00) | LMNATHRB | |
| SCHEMBL2722025 | 0.96 | LMNA (1.00) | LMNATHRB | |
| SCHEMBL249369 | 0.96 | LMNA (1.00) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028593-A | Solar cell, preparation method thereof, photovoltaic module, power utilization device and power generation device | 宁德时代新能源科技股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-116754533-A | Long afterglow homogeneous detection method | 复旦大学 | 2023-09-15 | — | — | CN | claimed |
| CN-115852507-A | Anti-static fabric and preparation method thereof | 扬州恒诚织布有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-112221538-A | Preparation method of fluoroalkyl modified cellulose supported palladium catalyst | 南京理工大学 | 2021-01-15 | — | — | CN | claimed |
| US-7612033-B2 | Methods for delivering compounds into a cell | IMARX PHARMACEUTICAL CORP. (US) | 2009-11-03 | — | — | US | claimed |
| EP-1015039-B1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2008-08-27 | — | — | EP | claimed |
| EP-0935415-B1 | IN VITRO METHODS FOR DELIVERING NUCLEIC ACIDS INTO A CELL | IMARX PHARMACEUTICAL CORP (US) | 2006-11-22 | — | — | EP | claimed |
| US-7105151-B2 | Oxygen delivery agents and uses for the same | IMARX THERAPEUTICS, INC. (US) | 2006-09-12 | — | — | US | claimed |
| US-20040176473-A1 | Methods for delivering compounds into a cell | IMARX PHARMACEUTICAL CORP. | 2004-09-09 | — | — | US | claimed |
| US-6743779-B1 | NUCLEIC ACID SEQUENCE AND A FLUORINATED COMPOUND AND A LIPID CARRIER. | IMARX PHARMACEUTICAL CORP. | 2004-06-01 | — | — | US | claimed |
| US-6143276-A | ADMINISTERING TO THE PATIENT A COMPOSITION COMPRISING A BIOACTIVE AGENT AND A GASEOUS PRECURSOR CAPABLE OF UNDERGOING PHASE TRANSITION TO A GAS AT A REGION OF ELEVATED TEMPERATURE IN THE PATIENT | IMARX PHARMACEUTICAL CORP. (US) | 2000-11-07 | — | — | US | claimed |
| EP-1046394-A2 | Novel compositions useful for delivering compounds into a cell | ImaRx Pharmaceutical Corp. (US) | 2000-10-25 | — | — | EP | claimed |
| EP-1015039-A1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0988061-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-29 | — | — | EP | claimed |
| EP-0935415-A1 | METHODS FOR DELIVERING COMPOUNDS INTO A CELL | IMARX PHARMACEUTICAL CORP. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1999025385-A1 | A METHOD OF INCREASING NUCLEIC ACID SYNTHESIS WITH ULTRASOUND | IMARX PHARMACEUTICAL CORP. (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1998057670-A1 | OXYGEN DELIVERY AGENTS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1998042384-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | claimed |
| WO-1997040679-A1 | METHODS FOR DELIVERING COMPOUNDS INTO A CELL | IMARX PHARMACEUTICAL CORP. (US) | 1997-11-06 | — | — | WO | claimed |
| EP-0395050-A1 | Process for the preparation of perfluorosuccinyl fluoride | AUSIMONT S.r.l. (IT) | 1990-10-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176473-A1 | Methods for delivering compounds into a cell | ABCB4, NPC1L1, IAPP | LMNA 420/4885THRB 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.